Primary Immune Thrombocytopenia Treated with Romiplostim (20140451)

Study identification

• EU PAS number:
  EUPAS11186
• Study ID:
  17010
• Official title and acronym:
  Primary Immune Thrombocytopenia Treated with Romiplostim (20140451)
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  No information provided.
• Study status:
  Finalised

Research institutions and networks

Institutions

Amgen

United States

Study timelines

Date when funding contract was signed

Actual:11/07/2014

Study start date

Actual:18/09/2015

Data analysis start date

Planned:22/01/2016

Actual:22/01/2016

Date of final study report

Planned:31/12/2016

Actual:03/01/2017

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Amgen

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)